This specific ISBN edition is currently not available.View all copies of this ISBN edition:
Glioblastoma is a refractory malignancy with limited treatment options at tumor recurrence. Only a small proportion of patients survive 2 years or longer with the current standard of care. Gene expression profiling can segregate newly diagnosed patients into groups with different prognoses, and these biomarkers are being incorporated into a new generation of personalized clinical trials. Using the experience from recently completed large scale, multi-faceted, randomized glioblastoma clinical trials, a new clinical trial paradigm is being established to move promising therapies forward into the newly diagnosed treatment setting. Upcoming trials using the immune check-point inhibitors are an example of this changing paradigm and these and other immunotherapies have potential as promising new treatment modalities for newly diagnosed GB patients. Proceeds from the sale of this book go to the support of an elderly disabled person.
"synopsis" may belong to another edition of this title.
Book Description CreateSpace Independent Publishing Platform, 2015. Condition: New. book. Seller Inventory # M1522853367